Skip to content
Screener

CeriBell, Inc. CBLL Stock-Based Comp

Stock-Based Comp at other companies

IAR
Integra LifeSciencesIART
$5.84M+10.4%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$2.22M+16.2%
iRadimed logo
iRadimedIRMD
$684K-17.2%
Teladoc Health logo
Teladoc HealthTDOC
$9.3M-58.4%
iRhythm Holdings, Inc. logo
iRhythm Holdings, Inc.IRTC
$20.04M-12.2%
ICU Medical logo
ICU MedicalICUI
$11.87M-17.9%

Other financials

Income statement

See full
Revenue$28.1M+32.5%
Gross profit$25.9M+38.8%
Operating income-$20.0M-33.6%
Net income-$19.3M-41.2%
EPS (diluted)-$0.51-34.2%

Balance sheet

See full
Cash & equivalents$32.7M-18.6%
Total debt$21.9M+1.7%
Total equity$128.3M-25.5%
Total assets$166.3M-19.9%

Cash flow

See full
Operating cash flow-$12.9M-70.8%
CapEx$17.0K-76.1%
Free cash flow-$12.9M-69.4%

Valuation

See full
Market cap$713.7M+50.8%
Enterprise value$702.95M+54.6%
P/S+0.9×

Profitability

See full
Gross margin88.9%+1.1pp
Operating margin-68.6%+1.5pp
Net margin-64.7%+0.9pp
FCF margin-53.7%+4.4pp

Returns & leverage

See full
Return on equity-43.9%
Debt / equity0.2×0.0×
Current ratio9.2×-4.1×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: CeriBell, Inc.’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342574
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense484659
Noncash lease expense(23)(50)
Stock-based compensation expense9,7215,515
Amortization of debt discount and accretion of premium on term loans150202
Accretion (amortization) of discount and premium on marketable securities(1,251)(487)
Loss on disposal of property and equipment and recorders6250
Changes in operating assets and liabilities:

Item 1. Financial Statements.

FAQ

What is CeriBell, Inc.'s stock-based comp?
CeriBell, Inc. (CBLL) reported stock-based comp of $6M in Q2 2026.
How has CeriBell, Inc.'s stock-based comp changed year-over-year?
CeriBell, Inc.'s stock-based comp increased by 89.4% year-over-year, from $3.17M to $6M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about CeriBell, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude